Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 8Colorectal Neoplasms 7Prostatic Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Endometrial Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Obesity 2Meningioma 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Disease 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Surgical Wound Dehiscence 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Small Cell Lung Carcinoma 1Skull Base Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1

Interventions

venetoclax 30obinutuzumab 22acalabrutinib 20Specimen Handling 19ibrutinib 16Cyclophosphamide 15Biopsy 15pirtobrutinib 14zanubrutinib 12fludarabine 12Rituximab 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 5Stem Cell Transplantation 4Blood Component Removal 4ARQ531 4idelalisib 3fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3tocilizumab 2polatuzumab vedotin 2Watchful Waiting 2Sirolimus 2Prednisone 2Pneumococcal Vaccines 2Lisaftoclax 2Leukapheresis 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Observation × Clear all
NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

Phase 2 Recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡